These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33886604)

  • 1. Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation.
    Bertrand D; Kaveri R; Laurent C; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Thierry A; François A; Hau F; Etienne I; Guerrot D; Farce F
    PLoS One; 2021; 16(4):e0249934. PubMed ID: 33886604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies Is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients.
    Villemaire M; Jouve T; Bourdin A; Janbon B; Pinel N; Tetaz R; Terrier N; Rostaing L; Masson D; Malvezzi P
    Exp Clin Transplant; 2019 Aug; 17(4):483-489. PubMed ID: 30346267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation.
    Miyake K; Okumi M; Kakuta Y; Unagami K; Furusawa M; Ishida H; Tanabe K
    Transpl Immunol; 2019 Dec; 57():101230. PubMed ID: 31398461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation.
    Contreras AG; Casillas-Abundis A; Alberú J; Llorente L; Lima G; Arvizu A; de Santiago A; Vilatobá M; Granados J; Morales-Buenrostro LE; Cruz R; Arreola-Guerra JM
    Transpl Immunol; 2018 Oct; 50():8-14. PubMed ID: 29885443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
    [No Abstract]   [Full Text] [Related]  

  • 8. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort.
    Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S
    Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.
    Lan JH; Gjertson D; Zheng Y; Clark S; ; Reed EF; Cecka MJ
    Am J Transplant; 2018 Dec; 18(12):2934-2944. PubMed ID: 29659162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
    Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of
    Pernin V; Beyze A; Szwarc I; Bec N; Salsac C; Perez-Garcia E; Mourad G; Merville P; Visentin J; Perrochia H; Larroque C; Couzi L; Le Quintrec M
    Front Immunol; 2020; 11():919. PubMed ID: 32670261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection.
    Sicard A; Meas-Yedid V; Rabeyrin M; Koenig A; Ducreux S; Dijoud F; Hervieu V; Badet L; Morelon E; Olivo-Marin JC; Dubois V; Thaunat O
    Kidney Int; 2017 Jul; 92(1):214-226. PubMed ID: 28318622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
    Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
    Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.
    Tatapudi VS; Kopchaliiska D; da Gente GJ; Buenaventura OF; Singh M; Laszik Z; Adey DB; Rajalingam R
    Ann Transplant; 2021 Dec; 26():e934175. PubMed ID: 34848674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.
    Courant M; Visentin J; Linares G; Dubois V; Lepreux S; Guidicelli G; Thaunat O; Merville P; Couzi L; Taupin JL
    Nephrol Dial Transplant; 2018 Oct; 33(10):1853-1863. PubMed ID: 29672702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.
    Zhang H; Zheng C; Li X; Fu Q; Li J; Su Q; Zeng L; Liu Z; Wang J; Huang H; Xu B; Ye M; Liu L; Wang C
    Front Immunol; 2020; 11():342. PubMed ID: 32184785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
    Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
    Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies.
    Kim JJ; Shaw O; Martin C; Michaelides G; Balasubramaniam R; Sebire NJ; Mamode N; Dorling A; Vaughan R; Marks SD
    Pediatr Nephrol; 2018 Jan; 33(1):167-174. PubMed ID: 28918487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies.
    Kovandova B; Slavcev A; Sekerkova Z; Honsova E; Trunecka P
    HLA; 2018 Dec; 92 Suppl 2():34-37. PubMed ID: 30054978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.